Mineralys Therapeutics In... (MLYS)
NASDAQ: MLYS
· Real-Time Price · USD
34.80
1.68 (5.07%)
At close: Sep 05, 2025, 3:59 PM
34.77
-0.09%
After-hours: Sep 05, 2025, 07:54 PM EDT
5.07% (1D)
| Bid | 32.58 |
| Market Cap | 2.31B |
| Revenue (ttm) | 34K |
| Net Income (ttm) | -190.77M |
| EPS (ttm) | -3.56 |
| PE Ratio (ttm) | -9.78 |
| Forward PE | -9.92 |
| Analyst | Buy |
| Ask | 35 |
| Volume | 3,091,677 |
| Avg. Volume (20D) | 1,260,956 |
| Open | 33.41 |
| Previous Close | 33.12 |
| Day's Range | 33.06 - 35.09 |
| 52-Week Range | 8.24 - 35.09 |
| Beta | -0.30 |
About MLYS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MLYS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MLYS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+2.45%
Mineralys Therapeutics shares are trading higher a...
Unlock content with
Pro Subscription
3 months ago
-1.44%
MLYS stock has given up its prior gain. Mineralys Therapeutics shares were trading higher after the company announced it presented Launch-HTN data at ESH 2025 and demonstrated its efficacy for over 1,000 patients.
3 weeks ago · seekingalpha.com
Mineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call TranscriptMineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Adam Scott Levy - CFO & Secretary Eric Warren - Chief Commercial Officer Jo...
